Praxis Precision Medicines Inc (PRAX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $299.02 (-3.69%), Market cap $9.36B, 52-week low–high $36.10 ~ $350.56.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epile
Financial statements, price targets, institutional (13F) holdings and related news for Praxis Precision Medicines Inc are updated in real time on BlackAll Trade.
Praxis Precision Medicines Inc trades at $299.02 (-3.69%). Real-time quotes and charts are available on BlackAll Trade.
Praxis Precision Medicines Inc has a market cap of about $9.36B.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-in